The Aortix technology is currently being evaluated for in-hospital therapy of cardiorenal syndrome patients and prevention of AKI associated with cardiac surgery. Credit: Procyrion, Inc / PRNewswire.

Procyrion has treated the first patients with its Aortix percutaneous mechanical circulatory support (pMCS) device in the A PRIORI (aortix therapy for perioperative reductIon of renal injury) pilot study.

The trial has been designed to assess the Aortix device’s ability to prevent acute kidney injury (AKI) during cardiac surgery.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Procyrion will recruit up to 50 patients for the study across four clinical sites in Australia, namely Royal Adelaide Hospital, Monash Health, Princess Alexandra Hospital and Macquarie University.

At the start of the scheduled surgical procedure, the Aortix pump is placed in the descending thoracic aorta through a percutaneous catheter procedure.

It helps to directly enhance perfusion to the kidneys while lowering cardiac energy requirements, stated the company.

The set-up of the pump can be completed within 15 minutes, and the intra-aortic placement helps avoid the risk of device-related thrombotic stroke or damage to the heart or valves.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The device’s design is said to leverage fluid entrainment to directly enhance renal artery flow and pressure, as well as enable physiologically natural therapy delivery.

According to the company, the Aortix pump should remain in place for up to 48 hours post-surgery to maintain increased renal perfusion.

This provides additional protection against postoperative risk factors for AKI, in addition to decreasing the workload for the recovering heart.

Procyrion president and CEO Eric Fain said: “The initiation of the A PRIORI study, after recently completing our pilot study in treating cardiorenal syndrome patients, is an exciting step that contributes to the growing body of evidence demonstrating the potential of the Aortix pump technology to improve outcomes for patients with cardiac and renal impairment.”